Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...

Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covid testing but is rapidly diversifying into other ...

UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. A live question and answer session ...

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...

Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the ...

Visit a quote page and your recently viewed tickers will be displayed here.

The latest price target for ProPhase Labs (NASDAQ:PRPH) was reported by HC Wainwright & Co. on February 21, 2024. The analyst firm set a price target for $11.00 expecting PRPH to rise to within 12 ...

In a challenging market environment, ProPhase Labs, Inc. (PRPH) stock has touched a 52-week low, reaching a price level of $1.99. This latest dip underscores a difficult period for the company, which ...

ProPhase Labs (NASDAQ:PRPH) has received an extension of 180 calendar days from The Nasdaq to regain compliance with the Nasdaq's minimum $1.00 bid price requirement. NASDAQ stated that it based its ...